FDA grants validate fast track status
-
Last Update: 2014-01-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Council for the promotion of drugs 2014-01-24 on the morning of January 23, 2014, bioalliance pharmaceutical company announced that the U.S Food and Drug Administration (FDA) has granted valid (clonidine lauriad) for the prevention and treatment of radiotherapy and / or chemotherapy for cancer patients with oral mucositis for rapid access Severe oral mucositis induced by intensive radiotherapy and chemotherapy is a highly disabling disease, especially in patients with head and neck tumors In severe cases, it can cause severe oral pain and eating disorders, requiring enteral or parenteral nutrition About 30% of patients have to be hospitalized, which leads to the interruption or delay of anti-cancer treatment and affects the chance of treatment success There are currently no approved therapeutic or preventive drugs Validic (clonidine lauriad) is a kind of oral mucosal adhesive based on lauriad's proprietary technology It releases high concentration of anti-inflammatory active ingredient (clonidine) in the radiotherapy position of head and neck cancer patients Original link: http://www.rttnews.com/2255654/bioalliance-pharma-says-fda-grants-valid-with-fast-track-design.aspx
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
